The TRITRIAL study: CAT change sub-analysis according to number of COPD exacerbations.

Richeldi,L.,Schino,P.,Bargagli,E.,Ricci,A.,Rocca,A.,Marchesani,F.,Pennisi,A.,Ciambellotti,L.,D'Amato,M.,Macagno,F.,Scaffidi Argentina,U.,Ingrassia,E.,Piraino,A.,Macagno,F.

DOI: https://doi.org/10.1183/13993003.congress-2024.pa4792

IF: 24.3

2024-11-01

European Respiratory Journal

Abstract:RATIONALE: TRITRIAL study evaluated change of Health Status (CAT score) in Italian COPD patients treated with extrafine triple inhaled therapy for 1 year. It is suggested that patients with 1 exacerbation can be considered at risk and take advantages from this treatment. OBJECTIVE: To investigate the change of Health status at 6 and 12 months stratifying patients according to the exacerbations' number in the previous year: Group A (1 exacerbation) and Group B (>2 exacerbations). METHODS: TRITRIAL study included COPD patients aged ≥ 40 years, ≥ 1 moderate-severe exacerbation in the previous year, CAT score >10 starting treatment with BDP/FF/G. A sub-analysis based on the number of previous moderate-severe exacerbations was performed. RESULTS: CAT score improved in both subgroups after 6 (mean difference -5,9 in group A and -4,6 in group B) and 12 months (mean difference -5,5 n group A and -5,3 in Group B) without any inter-group statistical difference (Fig. 1). CONCLUSIONS: This analysis suggests that starting treatment with extrafine BDP/FF/G provides a beneficial effect on patients' health status regardless of the number of exacerbations in the previous year. Fig. 1

respiratory system